Clinical Trials Browser

NCT04491942 2026-03-19

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT02466971 2026-03-18

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Phase 3 Active not recruiting

450 enrolled 11 charts

Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT04389632 2026-03-16

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Phase 1 Recruiting

1,006 enrolled

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT00421096 2026-03-13

GEMCOL

Phase 2 Terminated

19 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05521997 2026-03-13

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Phase 2 Not yet recruiting

42 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07216703 2026-03-13

TroFuse-036

Phase 3 Recruiting

1,023 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT04221945 2026-02-20

KEYNOTE-A18

Phase 3 Completed

1,060 enrolled 30 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

Phase 3 Completed

617 enrolled 29 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT00980954 2025-12-31

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Phase 3 Completed

236 enrolled 28 charts

Gynecologic

Uterine Cervical Neoplasms

NCT07276360 2025-12-11

HypoRTCx-UG

Phase 2 Not yet recruiting

278 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07232654 2025-12-01

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC

Phase 2 Recruiting

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT00957411 2025-11-24

CETUXICOL

Phase 2 Completed

76 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07244965 2025-11-24

Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

Phase 2 Not yet recruiting

42 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04982237 2025-11-19

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 3 Active not recruiting

445 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT02595879 2025-11-13

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Phase 1 Active not recruiting

21 enrolled 22 charts

Gynecologic

Uterine Cervical Neoplasms

NCT03738228 2025-11-12

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

Phase 1 Completed

40 enrolled 17 charts

Gynecologic

Uterine Cervical Neoplasms

NCT06535607 2025-10-29

eVOLVE-02

Phase 2 Recruiting

110 enrolled

GynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms

NCT07088731 2025-09-22

Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Phase 2 Not yet recruiting

180 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05570422 2025-09-11

A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01

Phase 1 Not yet recruiting

70 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

613 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04016389 2025-08-12